Found: 21
Select item for more details and to access through your institution.
Momelotinib versus Continued Ruxolitinib or Best Available Therapy in JAK Inhibitor-Experienced Patients with Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-2.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 9, p. 3722, doi. 10.1007/s12325-024-02928-4
- By:
- Publication type:
- Article
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 8, p. 2837, doi. 10.1007/s00277-024-05735-7
- By:
- Publication type:
- Article
SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 8, p. 506, doi. 10.1016/j.clml.2024.02.015
- By:
- Publication type:
- Article
Successful treatment with fludarabine and cyclophosphamide in a VEXAS syndrome patient with associated myelodysplastic syndrome: a case report and systematic review Polina.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.138373
- By:
- Publication type:
- Article
A multicenter phase Ib trial of the histone deacetylase inhibitor entinostat in combination with pembrolizumab in patients with myelodysplastic syndromes/neoplasms or acute myeloid leukemia refractory to hypomethylating agents.
- Published in:
- Annals of Hematology, 2024, v. 103, n. 1, p. 105, doi. 10.1007/s00277-023-05552-4
- By:
- Publication type:
- Article
Case report: Invasive fungal infection in a patient with a rare CVID-causing gene (TNFRSF13B) mutation undergoing AML treatment.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1017230
- By:
- Publication type:
- Article
Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis.
- Published in:
- EJHaem, 2022, v. 3, n. 4, p. 1346, doi. 10.1002/jha2.591
- By:
- Publication type:
- Article
Morphologic, immunophenotypic, and molecular genetic comparison study in patients with clonal cytopenia of undetermined significance, myelodysplastic syndrome, and acute myeloid leukemia with myelodysplasia‐related changes: A single institution experience
- Published in:
- International Journal of Laboratory Hematology, 2022, v. 44, n. 4, p. 738, doi. 10.1111/ijlh.13840
- By:
- Publication type:
- Article
Poster: MPN-127: Add-On Parsaclisib (a PI3Kδ Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S232, doi. 10.1016/S2152-2650(21)01457-9
- By:
- Publication type:
- Article
MPN-127: Add-On Parsaclisib (a PI3K5 Inhibitor) in Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib: Interim Analysis from a Phase 2 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S354, doi. 10.1016/S2152-2650(21)01819-X
- By:
- Publication type:
- Article
Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Essential Thrombocythemia Enrolled in the MOST Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, n. 7, p. 461, doi. 10.1016/j.clml.2021.02.011
- By:
- Publication type:
- Article
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
- Published in:
- Hematological Oncology, 2020, v. 38, n. 5, p. 654, doi. 10.1002/hon.2771
- By:
- Publication type:
- Article
Real-World Outcomes of Ruxolitinib Treatment for Polycythemia Vera.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Novel Agents in the Treatment of Polycythemia Vera Beyond Hydroxyurea.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S14, doi. 10.1016/j.clml.2018.06.038
- By:
- Publication type:
- Article
Pitfalls in Interventional Pain Medicine: Hyponatremia after DDAVP for a Patient with Von Willebrand Disease Undergoing an Epidural Steroid Injection.
- Published in:
- Case Reports in Anesthesiology, 2017, p. 1, doi. 10.1155/2017/6467090
- By:
- Publication type:
- Article
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF).
- Published in:
- British Journal of Haematology, 2017, v. 176, n. 1, p. 76, doi. 10.1111/bjh.14382
- By:
- Publication type:
- Article
A 26-Year-Old Female with Systemic Mastocytosis with Associated Myeloid Neoplasm with Eosinophilia and Abnormalities of PDGFRB, t(4;5)(q21;q33).
- Published in:
- Case Reports in Hematology, 2016, p. 1, doi. 10.1155/2016/4158567
- By:
- Publication type:
- Article
Ruxolitinib improves symptoms and quality of life in a patient with systemic mastocytosis.
- Published in:
- Biomarker Research, 2016, v. 4, p. 1, doi. 10.1186/s40364-016-0056-5
- By:
- Publication type:
- Article
Primary Myelofibrosis Presenting as Extramedullary Hematopoiesis in a Transplanted Liver Graft: Case Report and Review of the Literature.
- Published in:
- 2016
- By:
- Publication type:
- Case Study
Type 2 diabetes mellitus is associated with increased risk of pancreatic cancer: A veteran administration registry study.
- Published in:
- SAGE Open Medicine, 2016, v. 4, p. 1, doi. 10.1177/2050312116682257
- By:
- Publication type:
- Article
Palmar fasciitis with polyarthritis syndrome in a patient with breast cancer.
- Published in:
- Clinical Rheumatology, 2011, v. 30, n. 4, p. 569, doi. 10.1007/s10067-010-1592-2
- By:
- Publication type:
- Article